Mechanisms of bone metastasis formation;Mécanismes de formation des métastases osseuses

Journal de la Societe de Biologie

Volumn 201, Issue 3, 2007, Pages 229-236

  Peyruchaud, Olivier ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38049083085     PISSN: 12950661     EISSN: None     Source Type: Journal    
DOI: 10.1051/jbio:2007033     Document Type: Article

References (69)

1. Abrahamsen B. & Teng A. Y., Technology evaluation: denosumab, Amgen. Curr. Opin. Mol. Ther., 2005, 7, 604-610.
2. Adwan H., Bauerle T. J. & Berger M. R., Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther., 2004, 11, 109-120.
3. Aubin J. & Triffitt J., Mesenchymal stem cells osteoblast differenciation. In: Principles of Bone Biology. Bilezikian J. P., Raisz L. G, Rodan G. A. (eds). Academic Press, San Diego, 2002, 59-81.
4. Bellahcene A., Kroll M., Liebens F. & Castronovo V., Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res., 1996, 11, 665-670.
5. Bendre M. S., Gaddy-Kurten D., Mon-Foote T., Akel N. S., Skinner R. A., Nicholas R. W. & Suva L. J., Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res., 2002, 62, 5571-5579.
6. Blyth K., Cameron E. R. & Neil J. C., The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer, 2005, 5, 376-387.
7. Body J. J., Metastatic bone disease: clinical and therapeutic aspects. Bone, 1992. 13, S57-62.
8. Body J. J., Bartl R., Burckhardt P., Delmas P. D., Diel I. J., Fleisch H., Kanis J. A., Kyle R. A., Mundy G. R., Paterson A. H. & Rubens R. D., Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J. Clin. Oncol., 1998, 16, 3890-3899.
9. Boucharaba A., Serre C.-M., Gres S., Saulnier-Blache J. S., Bordet J.-C., Guglielmi J., Clezardin P. & Peyruchaud O., Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J. Clin. Invest., 2004, 114, 1714-1725.
10. Boucharaba A., Serre C. M., Guglielmi J., Bordet J. C., Clezardin P. & Peyruchaud O., The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc. Natl. Acad. Sci. USA, 2006, 103, 9643-9648.
11. Boyle W. J., Simonet W. S. & Lacey D. L., Osteoclast differentiation and activation. Nature, 2003, 423, 337-342.
12. Clines G. A. & Guise T. A., Mechanisms and treatment for bone metastases. Clin. Adv. Hematol. Oncol., 2004, 2, 295-301.
13. de la Mata J., Uy H. L., Guise T. A., Story B., Boyce B. F., Mundy G. R. & Roodman G. D., Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J. Clin. Invest., 1995. 95, 2846-2852.
14. De S., Chen J., Narizhneva N. V., Heston W., Brainard J., Sage E. H. & Byzova, T. V., Molecular pathway for cancer metastasis to bone. J. Biol. Chem., 2003, 278, 39044-39050.
15. Diel I. J., Solomayer E. F., Seibel M. J., Pfeilschifter J., Maisenbacher H., Gollan C., Pecherstorfer M., Conradi R., Kehr G., Boehm E., Armbruster F. P. & Bastert G., Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin. Cancer Res., 1999, 5, 3914-3919.
16. Fernandis A. Z., Prasad A., Band H., Klosel R. & Ganju R. K., Regulation of CXCR4mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene, 2004, 23, 157-167.
17. Fleisch H., Bisphosphonates in bone disease. Academic Press, 2000. Fourth edition.
18. Gilles C., Bassuk J. A., Pulyaeva H., Sage E. H., Foidart J. M. & Thompson E. W., SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res., 1998, 58, 5529-5536.
19. Guise T. A., Molecular mechanisms of osteolytic bone metastases. Cancer, 2000, 88, 2892-2898.
20. Guise T. A., Kozlow W. M., Heras-Herzig A., Padalecki S. S., Yin J. J. & Chirgwin J. M., Molecular mechanisms of breast cancer metastases to bone. Clin. Breast Cancer, 2005, 5 Suppl., S46-S53.
21. Guise T. A. & Mundy G. R., Cancer and bone. Endocr. Rev., 1998, 19, 18-54.
22. Guise T. A., Yin J. J., Taylor S. D., Kumagai Y., Dallas M., Boyce B. F., Yoneda T. & Mundy G. R., Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest., 1996, 98, 1544-1549.
23. Gunel N., Coskun U., Sancak B., Gunel U., Hasdemir O. & Bozkurt S., Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients. Cancer, 2002, 95, 663-667.
24. Hall C. L., Bafico A., Dai J., Aaronson S. A. & Keller E. T., Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res., 2005, 65, 7554-7560.
25. Hall C. L., Kang S., MacDougald O. A. & Keller E. T., Role of Wnts in prostate cancer bone metastases. J. Cell Biochem., 2006, 97, 661-672.
26. Hiraga T., Myoui A., Choi M. E., Yoshikawa H. & Yoneda T., Stimulation of Cyclooxygenase-2 expression by bone-derived transforming growth factor-(β) enhances bone metastases in breast cancer. Cancer Res., 2006, 66, 2067-2073.
27. Huang H., Groth J., Sossey-Alaoui K., Hawthorn L., Beall S. & Geradts J., Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin. Cancer Res., 2005, 11, 4357-4364.
28. Hughes P. E., Diaz-Gonzalez F., Leong L., Wu C., McDonald J. A., Shattil S. J. & Ginsberg M. H., Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J. Biol. Chem., 1996, 271, 6571-6574.
29. Ibrahim T., Leong I., Sanchez-Sweatman O., Khokha R., Sodek J., Tenenbaum H. C., Ganss B. & Cheifetz S., Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin. Exp. Metastasis, 2000, 18, 253-260.
30. Jackson J. G., Zhang X., Yoneda T. & Yee D., Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene, 2001, 20, 7318-7325.
31. Jones D. H., Nakashima T., Sanchez O. H., Kozieradzki I., Komarova S. V., Sarosi I., Morony S., Rubin E., Sarao, R. Hojilla C. V., Komnenovic V., Kong Y. Y., Schreiber M., Dixon S. J., Sims S. M., Khokha R., Wada T. & Penninger J. M., Regulation of cancer cell migration and bone metastasis by RANKL. Nature, 2006, 440, 692-696.
32. Kang Y., Siegel P. M., Shu W., Drobnjak M., Kakonen S. M., Cordon-Cardo C., Guise T. A. & Massague J., A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3, 537-549.
33. 3 integrin in osteotropic cancer cell invasion. J. Natl. Cancer Inst., 2004, 96, 956-965.
34. Karsenty G., The complexities of skeletal biology. Nature, 2003, 423, 316-318.
35. Knerr K., Ackermann K., Neidhart T. & Pyerin W., Bone metastasis: osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int. J. Cancer, 2004, 111, 152-159.
36. Komori T., Regulation of osteoblast differentiation by transcription factors. J. Cell Biochem., 2006, 99, 1233-1239.
37. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G. & Scully S., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 1998, 93, 165-176.
38. Logothetis C. J. & Lin S. H., Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer, 2005, 5, 21-28.
39. Morony S., Capparelli C., Sarosi I., Lacey D. L., Dunstan C. R. & Kostenuik P. J., Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res., 2001, 61, 4432-4436.
40. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M. E., McClanahan T., Murphy E., Yuan W., Wagner S. N., Barrera J. L., Mohar A., Verastegui E. & Zlotnik A., Involvement of chemokine receptors in breast cancer metastasis. Nature, 2001, 410, 50-56.
41. Mundy G., Oyojobi B., Taraianedes K., Dallas S. & Chen D., Cytokines and bone remodeling (second ed., 2001. Vol. 1). London: Academic Press.
42. Mundy G. R., Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002, 2, 584-593.
43. Mundy G. R., DeMartino S. & Rowe D. W., Collagen and collagen-derived fragments are chemotactic for tumor cells. J. Clin. Invest., 1981, 68, 1102-1105.
44. Nelson J., Bagnato A., Battistini B. & Nisen P., The endothelin axis: emerging role in cancer. Nat. Rev. Cancer, 2003, 3, 110-116.
45. Paget S., The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev., 1989, 8, 98-101.
46. Pecheur I., Peyruchaud O., Serr C. M., Guglielmi, J., Voland C., Bourre F., Margue C., Cohen-Solal M., Buffet A., Kieffer N. & Clezardin P., Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. Faseb J., 2002, 16, 1266-1268.
47. Peyruchaud O., Boucharaba A., Saulnier-Blache J. S., & Clezardin P., Lysophosphatidic acid: a new link between blood platelets and bone metastasis. Med. Sci. (Paris), 2005, 21, 353-355.
48. Sanders J. L., Chattopadhyay N., Kifor O., Yamaguchi T., Butters R. R. & Brown E. M., Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology, 2000, 141, 4357-4364.
49. Sasaki A., Boyce B. F., Story B., Wright K. R., Chapman M., Boyce R., Mundy G. R. & Yoneda T., Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 1995, 55, 3551-3557.
50. Schneider A., Kalikin L. M., Mattos A. C., Keller E. T., Allen M. J., Pienta K. J. & McCauley L. K., Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology, 2005, 146, 1727-1736.
51. Shulby S. A., Dolloff N. G., Stearns M. E., Meucci O. & Fatatis A., CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res., 2004, 64, 4693-4698.
52. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Luthy R., Nguyen H. Q., Wooden S., Bennett L. & Boone T., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89, 309-319.
53. Siwek B., Lacroix M., De Pollak C., Marie P. & Body J. J., Secretory products of breast cancer cells specifically affect human osteoblastic cells: partial characterization of active factors. J. Bone Miner. Res., 1997, 12, 552-560.
54. Smith M. C. P., Luker K. E., Garbow J. R., Prior J. L., Jackson E., Piwnica-Worms D. & Luker G. D., CXCR4 Regulates growth of both primary and metastatic breast cancer. Cancer Res., 2004, 64, 8604-8612.
55. Sun Y.-X., Schneider A., Jung Y., Wang J., Dai J., Wang J., Cook K., Osman N. I., Koh-Paige A. J., Shim H., Pienta K. J., Keller E. T., McCauley L. K. & Taichman R. S., Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research, 2005, 20, 318-329.
56. Taichman R. S., Cooper C., Keller E. T., Pienta K. J., Taichman N. S. & McCauley L. K., Use of the stromal cell-derived Factor-1/CXCR4 Pathway in Prostate Cancer Metastasis to bone. Cancer Res., 2002, 62, 1832-1837.
57. Teitelbaum S. L., Bone resorption by osteoclasts. Science, 2000, 289, 1504-1508.
58. Thomas R. J., Guise T. A., Yin J. J., Elliott J., Horwood N. J., Martin T. J. & Gillespie M. T., Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 1999, 140, 4451-4458.
59. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B. & Shaughnessy J. D. Jr., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med., 2003, 349, 2483-2494.
60. Trojan L., Schaaf A., Steidler A., Haak M., Thalmann G., Knoll T., Gretz N., Alken P. & Michel M. S., Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer. Res., 2005, 25, 183191.
61. Tsuda E., Goto M., Mochizuki S.-I., Yano K., Kobayashi F., Morinaga T. & Higashio K., Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications, 1997, 234, 137-142.
62. van der Pluijm, G., Que, I., Sijmons, B., Buijs, J. T., Lowik, C. W., Wetterwald, A., Thalmann, G. N., Papapoulos, S. E., & Cecchini, M. G.Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo. Cancer Res, 2005. 65, 7682-7690.
63. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S.-I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N. & Suda T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS, 1998, 95, 3597-3602.
64. Yeung F.,& Chung L. W., Molecular basis of co-targeting prostate tumor and stroma. J. Cell Biochem. Suppl., 2002, 38, 65-72.
65. Yin J. J., Mohammad K. S., Kakonen S. M., Harris S., Wu-Wong J. R., Wessale J. L., Padley R. J., Garrett I. R., Chirgwin J. M. & Guise T. A., A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA, 2003, 100, 10954-10959.
66. Yin J. J., Selander K., Chirgwin J. M., Dallas M., Grubbs B. G., Wieser R., Massague J., Mundy G. R. & Guise T. A., TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest., 1999, 103, 197-206.
67. Zayzafoon M., Abdulkadir S. A. & McDonald J. M., Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem., 2004, 279, 3662-3670.
68. Zhang J., Dai J., Qi Y., Lin D. L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J. & Keller E. T., Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest., 2001, 107, 1235-1244.
69. Zhang J., Dai J., Yao Z., Lu Y., Dougall W. & Keller E. T., Soluble receptor activator of nuclear factor {κ}B Fc diminishes prostate cancer progression in bone. Cancer Res., 2003, 63, 7883-7890.